Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 218
- Registration Number
- NCT00159783
A Study to Evaluate Ezetimibe in Korean Patients With Primary Hypercholesterolemia (0653-042)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 136
- Registration Number
- NCT00157911
Efficacy and Safety of Asenapine With Placebo and Haloperidol (41023)(P05926)(COMPLETED)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 460
- Registration Number
- NCT00156104
Ezetimibe (+) Simvastatin vs. Atorvastatin Comparative Study in DM or Metabolic Syndrome Patients (0653A-093)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 190
- Registration Number
- NCT00157924
Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314)
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 174
- Registration Number
- NCT00157963
A Study to Compare Effectiveness of Montelukast Sodium With Comparator in Mild to Moderate Persistent Asthmatics (0476-329)
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 31
- Registration Number
- NCT00157937
3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 488
- Registration Number
- NCT00159744
3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 489
- Registration Number
- NCT00159796
Efficacy and Safety of Asenapine With Placebo and Olanzapine (41021)(P05933)
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 417
- Registration Number
- NCT00156117
Efficacy and Safety of Asenapine With Placebo and Olanzapine (41022)(P05947)
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 277
- Registration Number
- NCT00151424
© Copyright 2024. All Rights Reserved by MedPath